Signifier Medical Technologies’ eXciteOSA Now Covered by Medicaid in South Carolina: Reaching a Wider Patient Population with Daytime Sleep Apnea Therapy

BOSTON, MA –Signifier Medical Technologies Limited (“Signifier”), a leader in medical technology for sleep-disordered breathing, is thrilled to announce that eXciteOSA therapy is now covered by South Carolina’s Healthy Connections Medicaid program. This significant milestone further broadens access to eXciteOSA’s revolutionary daytime therapy for obstructive sleep apnea, ensuring that more individuals can benefit from this innovative and effective treatment.

Sleep apnea affects millions of Americans, and if left untreated, can lead to severe health issues. eXciteOSA’s non-invasive daytime therapy has shown greater than 80% adherence, demonstrating the positive impact on the lives of those suffering from obstructive sleep apnea by offering an alternative to traditional night-time devices.

“We are thrilled that eXciteOSA is now covered by Medicaid in South Carolina,” states Akhil Tripathi, Director and Co-founder of Signifier. “This achievement represents a significant milestone in our mission to make high-quality sleep apnea care accessible to all individuals. We look forward to continuing to collaborate with Medicaid and healthcare providers to improve sleep health outcomes for patients across the state and the country.”

The decision by the South Carolina Department of Health and Human Services to cover eXciteOSA therapy through its Medicaid program underscores the importance of accessible, effective treatment options for sleep-disordered breathing. This coverage opens new doors for patients 18 and older who have previously had limited access to advanced treatments for obstructive sleep apnea. Recognizing the therapy’s potential to improve health outcomes and reduce overall healthcare costs, this decision marks a pivotal step towards inclusive healthcare.

Dr. Joshua Lennon states, “As a physician prescribing eXciteOSA, I’ve witnessed firsthand the transformative impact this therapy has had on my patients struggling with obstructive sleep apnea. With Medicaid coverage now available in South Carolina, I’m thrilled to see more individuals gaining access to this innovative solution.”

“Adding coverage of this new therapy aligns well with our agency’s mission to be boldly innovative in improving health and quality of life for South Carolinians,” states Robby Kerr, Director of Human and Health Services in South Carolina.

Signifier extends its gratitude to the South Carolina Department of Health and Human Services for their partnership in expanding access to obstructive sleep apnea therapy for Medicaid beneficiaries. The company continues to work closely with healthcare providers, payers, and patients to support the adoption and implementation of eXciteOSA therapy, ensuring that more individuals can experience its life-changing benefits.

About eXciteOSA®

eXciteOSA is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXciteOSA uses NMES to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices that are used while patients sleep, eXciteOSA is the first commercially available device used while awake.

Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials.

To learn more about eXciteOSA, please visit www.signifiermedical.com or www.exciteosa.com.

Contacts

Media:
Jay Cranston
Signifier Medical Technologies Limited
[email protected]

Investors and Partners:
Investor Relations
Signifier Medical Technologies Limited
[email protected]

New Published Study Explores Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled “Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea.” The study led by Drs. Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).

Recent estimates suggest that 55 million adults in the United States suffer from OSA, with over half falling into the mild range. Patients with mild OSA often experience a diminished quality of life compared to controls, and epidemiological analyses reveal increased risks of hypertension, diabetes, and abnormal fasting glucose among them. Despite the prevalence of OSA, the current standard of care, positive airway pressure (PAP) therapy, faces challenges such as low adherence and patient satisfaction, which creates a demand for alternative OSA treatment options.

The researchers in this study used a decision-analytic model to assess the incremental cost-effectiveness ratio (ICER) of neuromuscular electrical stimulation compared to no treatment and continuous positive airway pressure (CPAP) therapy. The analysis, conducted from the US healthcare system perspective, considered both direct medical costs and health outcomes measured in quality-adjusted life years (QALYs). The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment. Furthermore, it showed that neuromuscular electrical stimulation, depending on long-term adherence, may be preferred over CPAP therapy, suggesting that this alternative treatment approach could provide a valuable and more accessible option for individuals with mild OSA.

“We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea,” states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

While CPAP therapy has been the standard treatment for moderate to severe OSA, it has long been plagued with low adherence and low patient satisfaction. With over 14,000 patients being prescribed eXciteOSA, and real-world data demonstrating strong adherence of patients using therapy over 80% of days, this simple, non-invasive NMES therapy allows patients to complete a session for just 20 minutes during the day, offering them the freedom to breathe naturally, all night long, on their own.

Senior author Dr. Jan B. Pietzsch, who directed the study, emphasized the significance of the findings, stating, “Our research provides important insights into the potential cost-effectiveness of using neuromuscular electrical stimulation for individuals with mild obstructive sleep apnea that are relevant for patients, clinicians, and healthcare payers.”

This study contributes to the ongoing efforts to improve the quality of life for individuals with sleep apnea by exploring innovative and more accessible treatment alternatives. As researchers continue to explore the cost-effectiveness of various treatments, patients and clinicians will benefit from a wider range of evidence-based options for managing obstructive sleep apnea.

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep-disordered breathing. The Company is focused on developing and commercializing innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patients’ healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXciteOSA®

eXciteOSA is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXciteOSA uses NMES to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices that are used while patients sleep, eXciteOSA is the first commercially available device used while awake.
Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials.

To learn more about eXciteOSA, please visit www.signifiermedical.com or www.exciteosa.com.

Contacts

Media:
Jay Cranston
Signifier Medical Technologies LLC
[email protected]

Investors and Partners:
Investor Relations
Signifier Medical Technologies Limited
[email protected]

CMS Sets Pricing with New HCPCS Codes for eXciteOSA Therapy, Expanding Access to Innovative Daytime Sleep Apnea Treatment

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, welcomes the recent announcement by the Centers for Medicare & Medicaid Services (CMS) regarding the establishment of final HCPCS coding, benefit category determination, and payment determination for eXciteOSA therapy. This milestone decision represents a significant step toward expanding access to innovative and effective treatment options for individuals with sleep apnea, especially those covered by Medicare.

The recent CMS HCPCS Level II coding decision became effective on October 1, 2023. Here is the complete list of available codes for eXciteOSA.

HCPCS Codes and Descriptions

• E0490: Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote to describe eXciteOSA® with a remote.
• K1028: Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application.
• E0491: Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply.
• K1029: Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply.

Sleep apnea affects 55 million adults in the US, and if left untreated, it can lead to serious costly comorbidities, including cardiovascular disease, respiratory diseases, and metabolic disorders, resulting in increased hospital visits and healthcare costs. While continuous positive airway pressure (CPAP) therapy has been the standard treatment for moderate to severe OSA, it has long been plagued with low adherence and low patient satisfaction. eXciteOSA has shown greater than 80% adherence through the simplicity and convenience of a non-invasive daytime therapy that empowers patients to restore their nighttime breathing naturally.

These decisions made by CMS demonstrate their recognition of the clinical value and potential impact of eXciteOSA therapy. By providing a defined pricing structure, CMS is facilitating broader access to this innovative treatment, ensuring that eligible individuals covered by Medicare can benefit from its effects.

“This milestone accelerates our mission to improve patients’ lives by offering innovative and effective treatment options,” stated Director and Co-founder, Akhil Tripathi. “Demand is growing, with over 12,000 patients who have sought our therapy, and reimbursement will now help even more patients who suffer from OSA.”

As Signifier Medical continues to work closely with CMS, the company remains dedicated to supporting the adoption and implementation of eXciteOSA therapy across various healthcare settings. Through ongoing research, education, and collaboration, Signifier Medical strives to maximize the positive impact of its therapy and improve the quality of life for individuals living with sleep apnea.

About Signifier Medical Technologies

Signifier Medical is a pioneer in addressing the root causes of sleep-disordered breathing. The Company is focused on developing and commercializing innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patients’ healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXciteOSA®

eXciteOSA is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXciteOSA uses neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake.

Signifier Medical is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. To learn more about eXciteOSA, please visit www.signifiermedical.com or www.exciteosa.com.

Contacts

Media:
Jay Cranston
Signifier Medical Technologies LLC
[email protected]

Investors and Partners:
Mujtaba Chohan
Signifier Medical Technologies LLC
[email protected]

Signifier Medical Technologies Announces Upcoming Publication of Randomized Controlled Trial Results Examining High-Intensity (Active) Vs. Low-Intensity (Sham) Neuromuscular Electrical Stimulation in Patients for 6 Weeks

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, is pleased to announce that the publication of AEGIS clinical trial results is in press at the ERJ Open Research. The objective of the trial was to determine whether patients with mild obstructive sleep apnea (OSA) would adhere to eXciteOSA, a daytime neuromuscular electrical stimulation (NMES) therapy. Results showed high adherence, with approximately 90% of participants in each arm adherent to NMES. This trial demonstrates the potential of Signifier Medical’s innovative medical technology to significantly improve the lives of individuals suffering from obstructive sleep apnea (OSA).

“The encouraging results from our first randomized controlled trial further validate the data from our previous studies, and we’re thrilled to see how well patients accept the therapy,” says Co-founder and Director, Akhil Tripathi.

The current standard of care for treating mild OSA, positive airway pressure (PAP), has long been plagued with low adherence and low patient satisfaction. Clinical trials and observational studies indicate 25-46% of patients are not adherent to PAP.^1-3 There is also evidence that those with mild OSA are 34% less likely to adhere to PAP than those with moderate/severe OSA.⁴ Given that adherence to positive airway pressure (PAP) therapy in OSA is suboptimal, alternative strategies are needed, particularly for patients with mild OSA.

The AEGIS clinical trial was a randomized, double-masked, sham-controlled study to assess the adherence and overall impact of Signifier Medical’s innovative medical device, eXciteOSA, in managing and treating obstructive sleep apnea. Using NMES to “exercise” the upper airway muscles, eXciteOSA improves tongue muscle endurance and reduces the occurrence of airway collapse during sleep. The trial involved 40 patients and was conducted in collaboration with a network of renowned medical institutions and healthcare professionals.

Key findings of the AEGIS trial include:

High adherence: eXciteOSA for 20 minutes a day for 6-weeks in mild OSA was well accepted, with approximately 90% of the participants adhering to the required days of use.

Improvement in OSA severity: eXciteOSA was associated with approximately a 33% improvement in OSA severity after accounting for patient-related factors such as age, sex, race, body mass index, and the time in the supine position. In contrast, OSA severity remained unchanged in participants who received the sham device.

Improvement in Daytime Sleepiness: Participants in the active arm experienced improvements in daytime sleepiness, whereas no such change was noted in the sham arm.

“We are immensely pleased with the positive outcomes observed in the AEGIS clinical trial,” said Dr. Naresh Punjabi, the trial’s principal investigator. “This publication underscores our commitment to advancing healthcare and developing solutions that can make a meaningful difference in the lives of patients.”

Signifier Medical Technologies remains dedicated to further research, development, and collaboration with healthcare professionals to continue advancing medical technology and improving patient outcomes.

For further information about the AEGIS clinical trial please visit:

Neuromuscular Electrical Stimulation for Obstructive Sleep Apnea: Comparing Adherence to Active and Sham Therapy | European Respiratory Society (ersjournals.com)

About Signifier Medical Technologies

Signifier Medical is a pioneer in addressing the root causes of sleep-disordered breathing. The Company is focused on developing and commercializing innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patients’ healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXciteOSA®

eXciteOSA is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXciteOSA uses neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake.

Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. Randomized trials are in progress to understand the impact of therapy relative to usual care without treatment (NCT05183009; NCT05252156), and the impact of therapy amongst those with moderate OSA (NCT05252156).

To learn more about eXciteOSA, please visit www.signifiermedical.com or www.exciteosa.com.

Contacts

Media:
Jay Cranston
Signifier Medical Technologies LLC
[email protected]

Investors and Partners:
Mujtaba Chohan
Signifier Medical Technologies LLC
[email protected]

 

References:

1. Hwang D, Chang JW, Benjafield AV, Crocker ME, Kelly C, Becker KA, Kim JB, Woodrum RR, Liang J, Derose SF. Effect of Telemedicine Education and Telemonitoring on Continuous Positive Airway Pressure Adherence. The Tele-OSA Randomized Trial. Am J Respir Crit Care Med 2018;197(1):117-126.
2. Cistulli PA, Armitstead J, Pepin JL, Woehrle H, Nunez CM, Benjafield A, Malhotra A. Short-term CPAP adherence in obstructive sleep apnea: a big data analysis using real world data. Sleep Med 2019;59(114-116.
3. Patel SR, Bakker JP, Stitt CJ, Aloia MS, Nouraie SM. Age and Sex Disparities in Adherence to CPAP. Chest 2021;159(1):382-389.
4. Jacobsen AR, Eriksen F, Hansen RW, Erlandsen M, Thorup L, Damgard MB, Kirkegaard MG, Hansen KW. Determinants for adherence to continuous positive airway pressure therapy in obstructive sleep apnea. PLoS One 2017;12(12): e0189614.

Neuromuscular Electrical Stimulation as a treatment for obstructive sleep apnea gains traction with a recently announced World Sleep 2023 Congress symposium

BOSTON and LONDON – September 26, 2023, Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston- and London-based medical technology company, is excited to announce that the presentation “Neuromuscular Electrical Stimulation: A Novel Approach for Treatment of Obstructive Sleep Apnea” will be included in the prestigious World Sleep 2023 Congress. Since its FDA De Novo authorization in 2021, Signifier Medical has been a leader in applying neuromuscular electrical stimulation (NMES) to obstructive sleep apnea (OSA).

The NMES-for-OSA World Sleep presentation will be led by doctors Alexandre Abreu, Atul Malhotra, Adrian Williams, Marina Carrasco, and Naresh Punjabi. These leaders in sleep medicine will dive into the innovative research and clinical findings that demonstrate the efficacy and unique benefits of NMES in treating OSA. At this session, attendees can expect to gain an understanding of the therapy’s mechanism of action, clinical trial results, and its benefits on patient quality of life.

“We look forward to sharing our research and engaging with sleep medicine professionals from around the world at the World Sleep 2023 Congress,” added Dr. Naresh Punjabi. “By collaborating and exchanging ideas, we can collectively work towards improving the lives of individuals affected by sleep disorders.”

The inclusion of NMES in the World Sleep presentation reinforces the importance of expanding the portfolio of treatment options to treat OSA patients. Over 12,000 patients have started Signifier Medical’s eXcite^OSA® innovative NMES therapy. They achieve over 80% therapy adherence. This high adherence is enabled by the simplicity and low burden of an NMES-based therapy, coupled with a digital platform and Sleep Advocate coaching.

“We are thrilled that the importance of NMES to meet the unmet needs of OSA patients is being recognized in a World Sleep session“, said Akhil Tripathi, Director, and Co-founder. “This recognition affirms the significance of our research and the potential of neuromuscular electrical stimulation as a novel and effective approach in treating obstructive sleep apnea.”

The World Sleep 2023 Congress is scheduled for October 20-25, 2023, in Rio de Janeiro, Brazil. The NMES presentation will take place on Tuesday, October 24^th, from 10:45 a.m. to 12:15 p.m. Attendees can also visit the Signifier Medical booth #196 to speak with device experts and learn more about eXcite^OSA®.  throughout the conference. For more information on the presentation at the World Sleep 2023 Congress, please visit:

https://ws2023.abstractserver.com/program/#/details/sessions/316

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep-disordered breathing. The Company is focused on developing and commercializing innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patients’ healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXcite^OSA®

eXcite^OSA® is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXcite^OSA® uses neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices which are used while patients sleep, eXcite^OSA® is the first commercially available device used while awake, for just 20 minutes a day.

Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. Randomized trials are in progress to understand the potential placebo effect (NCT04974515), the impact of therapy relative to usual care without treatment (NCT05183009; NCT05252156), and the impact of therapy amongst those with moderate OSA (NCT05252156).

For more information, please visit www.signifiermedical.com or www.exciteosa.com.

Contacts

Media:
Jay Cranston
Signifier Medical Technologies Inc
[email protected]

Investors and Partners:
Mujtaba Chohan
Signifier Medical Technologies Inc
[email protected]

Appointment of new Board

BOSTON and LONDON – Aug 25, 2023

Signifier Medical Technologies Limited is delighted to announce the successful appointment of its new Board members: Shahzada Ahmed, John Bentley, Mujtaba Chohan, Rupert Connell, Rupert Reid, Andrew Schumer and Yasser Zayni.

 

John Bentley, Board Member, said “Signifier is in a really exciting period. The Board is looking forward to working with co-Founder Akhil Tripathi to drive the company as a leader in the sleep therapy sector”.

 

Signifier Medical Technologies Announces Partnership with Sunrise, the company revolutionizing home sleep testing for sleep apnea diagnosis

BOSTON and LONDON – May 9, 2023, Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, is proud to announce its partnership with Sunrise, a health tech company that offers a quick and easy way to help in the diagnosis of sleep apnea from home. This collaboration combines Sunrise’s cutting-edge artificial intelligence solutions and the innovative technologies of daytime sleep apnea therapy, eXcite^OSA, to improve patient care through more efficient diagnostics and treatments.

Founded in 2015, Sunrise aims to democratize access to care for sleep apnea syndrome by bringing clinical quality directly into the patient’s home. Its artificial intelligence-powered technology analyses a new signal on the human body, mandibular jaw movements, and other standard apnea signals, from a single sensor simply placed on the chin.

“We are excited to partner with Signifier Medical Technologies, starting with the UK market, and offer our innovative home sleep test to more patients suffering from OSA,” said Laurent Martinot, CEO of Sunrise.

The integrated solutions of Sunrise’s customized personal home sleep testing and Signifier Medical’s patient management portal will enable healthcare providers to gather comprehensive data on their patients’ day-to-day clinical experiences while providing tools for them to understand the unique needs of each individual better and optimize patient outcomes. With a common goal of improving patients’ lives through better sleep, Signifier Medical and Sunrise hope to create a future where better healthcare is available for all.

Akhil Tripathi, Signifier’s co-founder, and CEO, said, “We look forward to offering this innovative home sleep test to provide millions of patients suffering from OSA with easier access to diagnostics and personalized treatment.”

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep-disordered breathing. The Company is focused on developing and commercializing innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patients’ healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXcite^OSA®

eXcite^OSA is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXcite^OSA uses neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices which are used while patients sleep, eXcite^OSA is the first commercially available device used while awake.

Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. Randomized trials are in progress to understand the potential placebo effect (NCT04974515), the impact of therapy relative to usual care without treatment (NCT05183009; NCT05252156), and the impact of therapy amongst those with moderate OSA (NCT05252156).

For more information, please visit www.signifiermedical.com or www.exciteosa.com.

Contacts

Media:
Jay Cranston
Signifier Medical Technologies Inc
[email protected]

Investors and Partners:
Ekin Sezgen
Signifier Medical Technologies Inc
[email protected]

Signifier Medical Technologies Wins Edison Award for Innovative Sleep Apnea Treatment

BOSTON and LONDON – April 20, 2023, Signifier Medical Technologies, a leading medical device company, has been honored with a prestigious Edison Award for its innovative sleep apnea treatment, eXcite^OSA®. The Edison Awards, named after Thomas Alva Edison, recognize the most innovative and game-changing products, services, and business leaders across the globe.

eXcite^OSA® is the world’s first and only FDA-authorized, clinically proven daytime therapy for mild obstructive sleep apnea (OSA). It is a non-invasive, easy-to-use, and portable solution to help people breathe normally and naturally all night without needing a wearable medical device or a surgical implant. The therapy uses neuromuscular electrical stimulation (NMES) to improve the endurance of the tongue muscles and reduce airway collapse during sleep. This results in a significant reduction in the number of apnea and hypopnea events, and improvements in sleep quality and daytime function.

“We are thrilled to be recognized by the Edison Awards for our groundbreaking work in sleep apnea treatment,” said Akhil Tripathi, CEO of Signifier Medical Technologies. “eXcite^OSA® provides a new therapy option for millions of people worldwide who suffer from sleep apnea. Our device offers a non-invasive, effective, and comfortable alternative to traditional sleep apnea treatments.”

The Edison Award is a testament to Signifier Medical Technologies’ commitment to revolutionizing healthcare through innovative solutions that meet the needs of both patients and healthcare professionals alike.

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep-disordered breathing. The Company focuses on developing and commercializing innovative and non-invasive solutions to help restore nighttime breathing – naturally. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patients’ healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXcite^OSA®

eXcite^OSA is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXcite^OSA uses neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices which are used while patients sleep, eXcite^OSA is the first commercially available device used while awake, for just 20 minutes a day.

Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. Randomized trials are in progress to understand the potential placebo effect (NCT04974515), the impact of therapy relative to usual care without treatment (NCT05183009; NCT05252156), and the impact of therapy amongst those with moderate OSA (NCT05252156).

For more information, please visit www.signifiermedical.com or www.exciteosa.com.

Contacts

Media:
Jay Cranston
Signifier Medical Technologies Inc
[email protected]

Investors and Partners:
Ekin Sezgen
Signifier Medical Technologies Inc
[email protected]

Signifier Medical Technologies Reaches a Wider Patient Population with FDA Approval to Remove Dental Contraindications for eXciteOSA

February 22, 2023 02:03 PM Eastern Standard Time

BOSTON & LONDON–(BUSINESS WIRE)–Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces the FDA approval to remove dental contraindications for eXcite^OSA. This opens the door for doctors and other providers to prescribe eXcite^OSA on a more widespread basis.

Based on an observational study conducted by Signifier Medical, the data demonstrated no significant difference in the occurrence of eXcite^OSA side effects amongst those with intraoral metal and those without intraoral metal dental work. As a result of these findings, the FDA has approved the removal of temporary or permanent metal implants, dental braces, and intraoral metal prosthesis, restorations, and appliances from contraindications. This meaningfully expands the number of patients who can benefit from a daytime therapy, with no nighttime wearable, for mild obstructive sleep apnea and snoring.

“It’s a good thing when the FDA removes a barrier that didn’t make sense to us as clinicians. The exclusion because of metal restorations made it more difficult to talk to non-dentist medical colleagues. Now, with the restriction lifted, we can go about finding the best therapy for the individual patient,” said Steve Carstensen, DDS, Co-founder of Premier Sleep Associates, the Director of Education for Airway Technologies, and Chief Dental Editor for Dental Sleep Practice Magazine.

In the study, Signifier gathered therapy experience data from 499 real-world users of eXcite^OSA, including both civilian and Veteran patients. The focus of the study was primarily on the occurrence of side effects amongst patients with and without intraoral metal dental work and/or jewelry. Participants were asked to report the frequency, level of discomfort, and duration of eXcite^OSA side effects. A thorough intraoral/dental history was obtained, focused on the presence of intraoral metal.

“A large number of Veterans were previously deemed ineligible for eXcite^OSA for mild OSA/simple snoring because of the dental contraindications. This latest development is going to be well-received by VA clinics and patients across the country,” said Dr. Brandon Nokes, Director of Hypoglossal Nerve Stimulation at VA San Diego.

This study demonstrates the low-risk profile of eXcite^OSA — a novel medical therapy that was authorized in the FDA De Novo process. This important milestone moves eXcite^OSA, which treats one of the root causes of OSA, one step closer to being a first-line therapy for millions of people suffering with mild sleep apnea and snoring.

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep disordered breathing. The Company is focused on the development and commercialization of innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patients’ healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXcite^OSA®

eXcite^OSA is a revolutionary daytime therapy for sleep disordered breathing. Clinically proven to target a common root cause of OSA, eXcite^OSA improves daytime sleepiness and sleep quality. Nearly one billion adults aged 30 to 69 years globally are estimated to suffer from OSA, which is a serious medical condition associated with health problems such as high blood pressure and increased risks of heart attack, stroke, or death.

A major underlying cause of OSA is reduced endurance of the upper airway muscles, allowing the tongue to fall back and block the upper airway. By using neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, eXcite^OSA works the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep.

Unlike other devices which are used while patients sleep, eXcite^OSA is the first commercially available device used while awake. The full benefits of the daytime therapy are realized without patient use during sleep.

Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. Randomized trials are in progress to understand the potential placebo effect (NCT04974515), the impact of therapy relative to usual care without treatment (NCT05183009; NCT05252156), and the impact of therapy amongst those with moderate OSA (NCT05252156).

To learn more about eXcite^OSA, please visit www.signifiermedical.com or www.exciteosa.com.

For more information on the dental study, please email [email protected].

Contacts

Media:
Jay Cranston
Signifier Medical Technologies Inc
[email protected]

Investors and Partners:

Ekin Sezgen
Signifier Medical Technologies Inc
[email protected]

Signifier Medical Technologies Announces Participation In Piper Sandler Healthcare Conference

December 1, 2022 – Signifier Medical Technologies, a medical technology company developing innovative sleep-disordered breathing products for use in the homecare setting, will be presenting at the Piper Sandler Healthcare Conference today.

Signifier Medical Technologies is scheduled to present at 9 a.m. at the 34^th annual healthcare conference at Piper Sandler

Conference Theme: Delivering a thoughtful perspective on tomorrow’s trends
The goal of each conference is to bring together key industry executives, investors and our own professionals to provide multiple perspectives, investigate critical trends and identify the leaders in the markets that are driving our economy.

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep disordered breathing. The Company is focused on the development and commercialization of innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies improving population health, increase the quality of patients’ experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXcite^OSA®

eXcite^OSA is a revolutionary daytime therapy device for sleep disordered breathing. Clinically proven to target a common root cause of OSA, eXciteOSA improves daytime sleepiness and sleep quality. Nearly one billion adults aged 30 to 69 years globally are estimated to suffer from OSA, which is a serious medical condition associated with health problems such as high blood pressure and increased risks of heart attack, stroke, or death.

A major underlying cause of OSA is the upper airway muscles lack endurance during sleep and the tongue falls back, blocking the upper airway. By using neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, eXciteOSA works the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep.

Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake. The full benefits of the daytime therapy are realized without patient use during sleep.

For more information, please visit www.signifiermedical.com or www.exciteosa.com

Contacts

Marketing:
[email protected]
+1 (844) 645 3672

Investors and Partners:
Alastair Maxwell
Signifier Medical Technologies Inc
[email protected] 

Signifier Medical Technologies’ eXciteOSA®, the only FDA-authorized daytime therapy for primary snoring and mild obstructive sleep apnea, demonstrates real-world adherence to treatment of over 80%

Signifier Medical Technologies Announces Publication of Peer-Reviewed Analysis Demonstrating Improvement in Obstructive Sleep Apnea Severity with Neuromuscular Electrical Stimulation

Signifier Medical Technologies is granted HCPCS Codes for eXcite^OSA to help patients access innovative technology

CMS establishes new Level II HCPCS codes to describe eXcite^OSA, the first-ever daytime treatment for obstructive sleep apnea

BOSTON, U.S.A., February 22, 2022 (BUSINESS WIRE) — Signifier Medical Technologies LLC, a Boston-based medical technology company, announced today that the Centers for Medicare & Medicaid Services (CMS) established two new Level II Healthcare Common Procedure Coding System (HCPCS) codes to describe eXcite^OSA, the first-ever FDA authorized de-novo device for daytime treatment of mild obstructive sleep apnea (OSA) and primary snoring. The CMS coding decision was published on February 16, 2022 and the following codes will become effective on April 1, 2022:

 

HCPCS Code	Description
K1028	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle for the reduction of snoring and obstructive sleep apnea, controlled by phone application.
K1029	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply.

 

“We welcome CMS’ decision to establish two new codes to describe the eXcite^OSA device”, said Akhil Tripathi, Chief Executive Officer at Signifier. “With over 3,000 patients treated with eXcite^OSA, we have seen strong demand for our therapy. Establishing codes marks an important milestone for physicians, health systems, DME suppliers, payers and patients alike, and will enable Signifier to demonstrate further the real world benefits of improved outcomes, cost savings and significantly improved quality of care for patients. Reimbursement will help patients in the US who suffer from sleep disordered breathing with an option to obtain a new, effective daytime treatment.”

OSA is a progressive disease, often starting with primary snoring, affecting nearly 1 billion adults aged 30 to 69 globally.¹   Used for only 20 minutes per day during the initiation period, and then twice per week thereafter for maintenance, eXcite^OSA targets a primary root cause of mild OSA by delivering neuromuscular electric stimulation to increase tongue muscle endurance.

“HCPCS codes play a critical role in providing patients with access to new medical devices, often improving payment options and healthcare decisions,” said Dr. Marc Benton, a New Jersey-based pulmonologist and sleep medicine specialist. “The eXcite^OSA is a non-invasive, easy to use therapy that does not require patients to wear any sort of device during the night. Once reimbursement is established, eXcite^OSA will be easier to access for a broader and more diverse population of patients suffering from sleep apnea, and I’m excited to share the good news with all of them.”

The CMS decision can be viewed at: https://www.cms.gov/files/document/2021-hcpcs-application-summary-biannual-2-2021-non-drug-and-non-biological-items-and-services.pdf

 

 

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep disordered breathing. We are focused on the development and commercialization of innovative and non-invasive solutions for patients with conditions such as Obstructive Sleep Apnea and primary snoring. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies that improve population health, increase the quality of patients’ experience and generate healthcare savings. Signifier has offices in London (UK), Needham (Massachusetts, USA) and Berlin (Germany).

 

About eXcite^OSAâ

eXcite^OSA is a revolutionary daytime therapy device for sleep disordered breathing. Clinically proven to target a common root cause of OSA, eXcite^OSA improves sleep quality, improves health and increases quality of life. Nearly one billion adults aged 30 to 69 years globally are estimated to suffer from OSA, which is a serious medical condition associated with health problems such as high blood pressure and increased risks of heart attack, stroke or death.^1-10

A major underlying cause of OSA is that the upper airway muscles lack endurance during sleep and the tongue falls back, blocking the upper airway. By using neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, eXcite^OSA works the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep.

Unlike other devices which are used while patients sleep, eXcite^OSA is the first commercially available device used awake. The full benefits of the daytime therapy are realized without patient use during sleep.

 

About Snoring and Obstructive Sleep Apnea

Nearly one billion adults aged 30 to 69 years are estimated to have OSA globally.¹ OSA and snoring are problems for many people whose tongue muscles relax during sleep, causing airway collapse and decreased oxygen intake, which causes the sleeper to stop and restart breathing during sleep, often jolting them awake.^15-16

OSA is a serious medical condition associated with health problems like high blood pressure and increased risks of heart attack, stroke, or death.^2-9 OSA and snoring also affect patients’ partners and family members, consequently putting strain on relationships.^15-16

For more information, please visit www.signifiermedical.com or www.exciteosa.com

 

Contacts

[email protected]

+1 (844) 645 3672

 

References

1. Benjafield, A. V., Ayas N T, Eastwood P R et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019; 7: 687-698.
2. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342:1378–1384. [PubMed: 10805822]
3. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122:352– 360. [PubMed: 20625114]
4. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnoea as a risk factor for stroke and death. N Engl J Med. 2005; 353:2034–2041. [PubMed: 16282178]
5. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea- hypopnea and incident stroke: The Sleep Heart Health Study. Am J Respir Crit Care Med. 2010; 182:269–277. [PubMed: 20339144]
6. Peker Y, Hedner J, Norum J, et al. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnoea: a 7-year follow-up. Am J Respir Crit Care Med. 2002; 166:159– 165. [PubMed: 12119227]
7. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005; 365:1046–1053. [PubMed: 15781100]
8. Peppard PE, Szklo-Coxe M, Hla KM, et al. Longitudinal association of sleep-related breathing disorder and depression. Arch Intern Med. 2006; 166:1709–1715. [PubMed: 16983048]
9. Kendzerska T, Gershon AS, Hawker G, et al. Obstructive sleep apnoea and incident diabetes: a historical cohort study. Am J Respir Crit Care Med. 2014; 190:218–225. [PubMed: 24897551]
10. Johnson KG and Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J of Clinical Sleep Med 2010;6(2):131-7
11. Baptista et al. Daytime Neuromuscular Electrical Therapy of Tongue Muscles in Improving Snoring. 2021
12. et al. A novel intraoral neuromuscular stimulation device for treating sleep-disordered breathing. Sleep Breath. 2021.
13. Data on File. Signifier Medical Technologies
14. Davey, M. J. Epidemiological study of snoring from a random survey of 1075 participant. British Snoring and Sleep Apnoea Association. 2002; Available at: https://britishsnoring.co.uk/pdf/epidem.pdf
15. Levy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers 2015; 1: 15015.
16. Luyster FS. Impact of Obstructive Sleep Apnea and Its Treatments on Partners: A Literature Review. J Clin Sleep Med. 2017;13(3):467-477.

eXciteOSA® Daytime Sleep Apnea Therapy Device Surpasses 50,000 Patient Session Milestone

Driving comfort and relief for patients with snoring and mild obstructive sleep apnea

BOSTON, U.S.A. and LONDON, U.K., October 12, 2021 (BUSINESS WIRE) — Signifier Medical Technologies Ltd, an innovator in the sleep-disordered breathing market, announced today that it has hit the 50,000 therapy session milestone with its innovative eXcite^OSA® sleep device.

Following FDA authorization and clearance for marketing in February 2021, eXcite^OSA has been quickly adopted by physicians and patients alike. The first of its kind, eXcite^OSA is a daytime treatment for snoring and mild obstructive sleep apnea (OSA). Used for only 20 minutes per day for six weeks and then twice per week thereafter for maintenance, the eXcite^OSA therapy is clinically proven to improve quality of sleep by significantly reducing mild OSA and snoring^1,2.

“We are thrilled with what this milestone represents for the improvement of patient care,” said Akhil Tripathi, CEO, and co-founder of Signifier Medical Technologies. “Being a comfortable and effective treatment has helped patients stay adherent to their therapy and feel the difference. 50,000 sessions is only the beginning, and we look forward to supporting the millions of people who suffer from mild OSA and snoring.”

Unlike devices used while patients are asleep, eXcite^OSA is the first marketed device designed to be used while awake. It works by applying neuromuscular electrical stimulation (NMES) on the genioglossus muscle – the major muscle that forms the tongue mass. NMES creates contractions of the tongue muscle, enhancing function and endurance so that after 6 weeks of therapy, the tongue stays in an ideal position for optimal airflow.

“eXcite^OSA has been a life-saver for me and my family. The device has significantly reduced my snoring after just 2 weeks of use,” said Jessie Cadet-Legros, an eXcite^OSA patient. “It was easy to find 20 minutes during the day to use it and the results have paid off. My husband now sleeps better without my snoring, and so do I.”

OSA affects one in three adults – as many as 54 million Americans. Left untreated, obstructive sleep apnea can lead to serious complications such as hypertension, heart attack, cancer, and cognitive disorders. To learn more about eXcite^OSA, please visit www.eXciteosa.com

-END-

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring.

Signifier’s proprietary therapy, eXcite^OSA®, is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology authorized in the US for mild obstructive sleep apnea and primary snoring and is supported by clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1,2

References

1. Wessolleck E, Bernd E, Dockter S, Lang S, Sama A, Stuck BA. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie 2018;22(Suppl 2):47-52.
2. Baptista PM, Martinez Ruiz de Apodaca P, Carrasco M, et al. Daytime Neuromuscular Electrical Therapy of Tongue Muscles in Improving Snoring in Individuals with Primary Snoring and Mild Obstructive Sleep Apnea. J Clin Med 2021;10(9):1-11.

Signifier Medical Technologies Raises $35M in Series D Funding Round to Accelerate Commercialization of eXciteOSA Therapy

Rapidly commercializing eXciteOSA to treat millions of patients around the world suffering from primary snoring and mild obstructive sleep apnea (OSA).

Boston, MA, USA, and London, United Kingdom

July 27, 2021

eXciteOSA is a revolutionary daytime therapy device for sleep disordered breathing. Clinically proven to target a common root cause of OSA and snoring, eXciteOSA helps to improve sleep quality and give patients better health and a better quality of life.10, 11

A major underlying cause of snoring and OSA is that patients have abnormalities in upper airway muscle function, or the tongue lacks endurance during sleep and falls back, blocking the upper airway. eXciteOSA works by using neuromuscular electrical stimulation (NMES) to exercise those muscles, using safe, low-intensity impulses to stimulate the intrinsic and extrinsic pharyngeal and tongue muscles directly to improve muscle tone, strength, and endurance.

Unlike other devices which are used while patients sleep, eXciteOSA is the first device which is used exclusively while awake. The device rests on the tongue and stimulates the pharyngeal and tongue muscles directly to improve their endurance, much like going to the gym would improve any other muscle. The device has been designed to target a wide range of patients with mild OSA, in addition to primary snoring, by building endurance of the weak tongue and surrounding muscles. This then prevents the muscles from collapsing in the first place, tackling a root cause of mild OSA and snoring.

OSA is a serious medical condition associated with health problems like high blood pressure and increased risks of heart attack, stroke, or death.13 OSA and snoring do not just affect those suffering from them, but also their partners and family members, consequently putting strain on relationships.14, 15

Signifier Medical Receives Prestigious 2020 GOOD DESIGN Award for Superior Design Excellence

eXciteOSA® is the World’s First Daytime Therapy Targeting the Root Cause of Mild Obstructive Sleep Apnea and Snoring

Signifier® Medical Ushers In New Era of Treatment for Sleep Apnea and Snoring with FDA Authorization of eXciteOSA® Device

Revolutionary first-ever daytime treatment for mild obstructive sleep apnea and snoring will now be available in the United States

Signifier® Medical Technologies Announces Award of UK NHS Supply Chain Tender

Contract award will position Signifier as an approved NHS supplier
Contract will launch in May 2021, expected to drive UK sales of eXciteOSA® for sleep disordered breathing

Boston, MA, USA, and London, United Kingdom

December 22, 2020

Signifier Medical Technologies (“Signifier” or “the Company”), an innovator in the sleep disordered breathing market, is pleased to announce the successful award of the UK Non-invasive Ventilation, Sleep Therapy and Sleep Monitoring Tender, which will confirm Signifier as an approved supplier to the UK’s National Health Service (NHS).

This contract award gives Signifier direct access to the NHS supply chain, including the relevant coding, inventory and ordering systems, to enter the important UK NHS market. Yasser Zayni, Signifier’s Regulatory & Quality Director, was instrumental in the process and commented that “this award will help to accelerate patient access to our innovative technology across the UK.”

eXciteOSA® is the only clinically proven daytime intraoral neuromuscular stimulation device to improve the quality of sleep by reducing sleep apnea and snoring significantly when used for 20 minutes once a day for six weeks1-4. The device has been designed to treat a wide range of patients with mild obstructive sleep apnea (OSA), in addition to primary snoring, by building endurance of the weak tongue and surrounding muscles known to be root causes of these conditions.

Signifier has also focused on digital OSA therapy interfaces for patients and clinicians. An intuitive app for use alongside the eXciteOSA device motivates a patient to achieve high treatment compliance and to monitor progress. In addition, therapy data is available on Signifier’s clinician portal, enabling the medical community to monitor and track results.

With European CE Mark approval, the Company is planning for wider expansion to support the commercialization and reimbursement of eXciteOSA in the UK, Germany and other major European markets. The Company has also established its US office in Boston and is building commercial operations there ahead of the anticipated approval and launch of eXciteOSA in the important US market.

Akhil Tripathi, CEO of Signifier, commented: “The light touch nature of eXciteOSA and its digital user interface and companion app means that it is a product ideally suited to current times. The award of this NHS contract reflects the hard work and commitment of our employees and is an important pillar of our commercial launch strategy, which will focus on HCPs (Health Care Professionals). We have a unique product backed by excellent clinical data, which we believe can make a significant difference to the lives of many patients suffering from sleep disordered breathing conditions and we look forward to bringing this product to patients more widely.”

For more information, please contact:

Signifier Medical Technologies
Email: [email protected]
Tel: +44 (0)20 7096 0586

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring.

Signifier’s proprietary therapy eXciteOSA® is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for mild obstructive sleep apnea and snoring, supported by clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

About OSA and Snoring

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

References

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]

2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.

3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.

4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15 n=65). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

Signifier® Medical Technologies appoints Alastair Maxwell as Chief Financial Officer

Brings significant capital markets and strategic development expertise to support Company growth 29 years of Investment Banking experience at Kleinwort Benson, Morgan Stanley and Goldman Sachs

Boston, MA, USA, and London, United Kingdom

November 24, 2020

Signifier Medical Technologies (“Signifier/the Company”), an innovator in the sleep-disordered breathing market, is pleased to announce the appointment of Alastair Maxwell as Chief Financial Officer with immediate effect. He will be based in Boston and London and will be responsible for all aspects of the Company’s financial strategy, management, and operations including ensuring that the Company is adequately financed to meet its ambitious growth plans.

Mr. Maxwell has enjoyed a long and successful career in the investment banking industry where he worked for almost 30 years. This was most recently with Goldman Sachs from 2010 to 2016 where he was a Partner and Global Industry Group Co-Head with responsibility for relationships with a wide range of corporate and other clients.

Previous to this, he was with Morgan Stanley, most recently as Managing Director and Industry Head in the EMEA region, and prior to that with Dresdner Kleinwort Benson.

Prior to joining Signifier, Mr. Maxwell was Chief Financial Officer at NYSE-listed companies GasLog Ltd and GasLog Partners LP where he worked closely with the Board and senior management team to facilitate the growth of the business and to secure the funding required to support this growth.

During his career, Mr. Maxwell has been involved in a wide range of strategic and financing transactions, including equity, equity-linked, bond and bank financings for a variety of private and public companies.

Akhil Tripathi, CEO of Signifier commented: “This latest key appointment further rounds out our world-class leadership team. Alastair brings significant expertise to the Company in capital markets, fundraising, and corporate strategy. His global and US experience will be crucial in supporting Signifier and ensuring that we have access to the appropriate financing as we seek to rapidly expand our business.”

Alastair Maxwell added: “I am excited to be joining Signifier at this important time in its development. With the anticipated launch of eXciteOSA®, the Company is poised for significant growth. I look forward to utilizing my skills and network to work with Akhil and the rest of the team to help the Company realize its tremendous potential.”

For more information, please contact:

Signifier Medical Technologies
Email: [email protected]
Tel: +44 (0)20 7096 0586

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring.

Signifier’s proprietary therapy eXciteOSA® is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for mild obstructive sleep apnea and snoring, supported by clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

About OSA and Snoring

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

References

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]

2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.

3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.

4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15 n=65). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

Signifier® Medical Technologies appoints Jim Hinrichs, former CFO and Director of CareFusion and Alere, to its Board

Boston, MA, USA, and London, United Kingdom

November 12, 2020

Signifier Medical Technologies (“Signifier” or the “Company”), an innovator in the sleep-disordered breathing market, is pleased to announce the appointment of Jim Hinrichs to the Board of the Company. He joins existing Directors Kieran Gallahue (Chairman), Akhil Tripathi (CEO), Steffen Kastner, and Robert Sullivan.

Jim has 30 years of financial leadership experience in large and small organizations within the healthcare industry. Prior to his current board roles, Jim served as Chief Financial Officer (CFO) of multiple companies. These included Alere Inc, a publicly-traded diagnostic company, until its sale to Abbott Labs for approximately $8 billion; CareFusion Corporation, a publicly-traded medical technology company, until its sale to Becton Dickinson for approximately $12 billion; Sangstat Medical, a publicly-traded biotechnology company; and Cibus, a startup gene-editing company focused on the agriculture markets.

He previously served at Cardinal Health in various financial leadership positions having joined the company following more than a decade of finance and marketing roles at Merck & Co.

Jim currently serves as a Director and Chair of the Audit Committee at Orthofix Inc. (OFIX), Director and Chair of the Compensation Committee at Integer Holdings (ITGR), Lead independent director and Chair of the Audit Committee at Acutus Medical (AFIB), and Director and Chair of the Audit Committee at Outset Medical (OM).

Akhil Tripathi, CEO of Signifier, commented: “I am delighted to welcome Jim to the Board of Signifier. He brings tremendous industry experience and well-proven financial leadership and governance skills that will be invaluable in supporting the senior management team as we move to commercialize eXciteOSA for mild sleep apnea and snoring.”

Jim Hinrichs added: “Signifier Medical is poised to begin a phase of rapid expansion and growth with the potential to revolutionize treatment for patients with sleep-disordered breathing. I am excited to be working with the company at this pivotal stage and look forward to bringing my skills and experience to complement those of the existing Board.”

Mr. Hinrichs’s appointment follows the recent expansion of Signifier’s senior management team. In September, Signifier announced the appointment of Philip Hess, former President and CEO of Bose Corporation, as Chief Operating Officer based in Boston, USA, where Signifier is establishing its US operations. In October, Travis Nieman was appointed as Managing Director International, joining the company from Stryker Corporation.

For more information, please contact:

Signifier Medical
Email: [email protected]
Tel: +44 (0)20 7096 0586

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring.

Signifier’s proprietary therapy eXciteOSA® is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for mild obstructive sleep apnea and snoring, supported by clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

About OSA and Snoring

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

References

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]

2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.

3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.

4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15 n=65). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

Signifier® Medical Technologies appoints Travis Nieman as Managing Director International

Boston, MA, USA and London, United Kingdom

October 08, 2020

Senior appointment in preparation for commercialization in markets outside the USA of eXciteOSA®, a novel, non-invasive, daytime therapy for sleep-disordered breathing conditions

Signifier Medical Technologies (“Signifier”), an innovator in the sleep-disordered breathing market, is pleased to announce the appointment of Travis Nieman as Managing Director International. Mr. Nieman joins the company from Stryker where he was Managing Director International & Global Reimbursement, Stryker Ear Nose & Throat. He will be responsible for the commercial development of eXciteOSA® in all markets outside the USA.

Mr Nieman is a highly experienced commercial leader in healthcare with a proven track record in small and large organizations over more than 20 years. Prior to Stryker, he was a Director of International Marketing at Baxter and before that spent several years at Medtronic as Brand Manager Europe-Central Asia. Mr. Nieman began his career at The Coca-Cola Company.

Akhil Tripathi, CEO of Signifier commented: “We are very pleased to welcome Travis as the newest member of our senior management team. His skills and experience in healthcare device management, developing and launching new technologies, health economics outcomes research and market access, business development, and commercial leadership will be invaluable in driving the commercial strategy for eXciteOSA^® in international markets outside of the US. His appointment represents another key building block in our mission to bring our novel technology to markets globally.”

Travis Nieman added: “eXciteOSA^® is a highly innovative product and I believe represents a unique opportunity to improve the lives of many patients suffering from sleep-disordered breathing. We intend to build a seamless pathway for users including an integrated digital strategy that offers the potential to bring broader healthcare benefits to patients. I look forward to bringing my skills and experience to bear at Signifier Medical as we continue on this exciting phase of our journey over the next 12 months and beyond.”

Mr Nieman’s appointment further expands the senior management team. In September, Signifier announced the appointment of Philip Hess, former President and CEO of Bose Corporation, as Chief Operating Officer based in Boston, USA, where Signifier is establishing its US operations. In July, Signifier announced the appointment of Mr. Matt Sharris as Vice President of Sales for North America. We look forward to announcing further key appointments as we build out our world-class leadership team.

For more information, please contact:

Signifier Medical
Email: [email protected]
Tel: +44 (0)20 7096 0586

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions.

Signifier’s proprietary therapy eXciteOSA® is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for snoring and mild obstructive sleep apnea, supported by clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

References

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]
2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15 n=65). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

Signifier Medical Technologies Closes $10M Series C Funding Round

London, United Kingdom

September 16, 2020

Signifier Medical Technologies (“Signifier”), an innovator in the sleep-disordered breathing market, today announced it has closed a circa $10M Series C funding round led by Alan Howard, VC investor and co-founder of Brevan Howard. The proceeds from this latest successful fundraising will allow Signifier to invest further in its innovative and non-invasive solutions for patients with sleep-disordered breathing conditions.

The financing round also included participation from James Blair, a career healthcare venture capitalist and Partner/Co-founder of Domain Associates as an additional new investor in Signifier. Existing investors participating in the round included The Pritzker Organization and Signifier’s Chairman Kieran Gallahue, former CEO of both CareFusion, Inc. and Resmed Inc.

Alan Howard commented: “I look for companies that are addressing extensive market opportunities, are rapidly growing, and have experienced leadership teams. I strongly believe Signifier is one of those companies, and I am pleased to support its transformational innovation to address sleep and breathing disorders and chronic care management.”

Joseph Gleberman, Managing Director of The Pritzker Organization, added: “We are pleased to continue supporting Signifier’s breakthrough technology for treating both chronic snoring and obstructive sleep apnoea.”

James Blair noted: “I am delighted to become an investor in Signifier, which is combining the tools of information technology with the knowledge of leading physicians to improve the daily lives of millions of people suffering from sleep-disordered breathing both conveniently and inexpensively.”

Signifier is continuing to build its operations and infrastructure in preparation for global commercialization of its eXciteOSA® device for mild sleep apnoea, while expanding commercialization of its eXciteOSA® device for primary snoring.

Akhil Tripathi, CEO and co-founder of Signifier Medical added “I am delighted to have attracted such prominent and well-known investors in our latest financing round. Our non-invasive tongue muscle-neurostimulation devices are the first and only technologies being developed to solve the conditions of mild sleep apnoea and snoring and make a real impact on the lives of millions of people worldwide. We recently announced the appointments of Philip Hess, former President and CEO of Bose Corporation, as Chief Operating Officer based in Boston, US, as well as Matt Sharris as Vice President of Sales in the North American market and Steve Saunders as Head of Sales in EMEA. With the addition of this latest financing round we are well prepared to accelerate the commercial phase of our development.”

For more information, please contact:

Signifier Medical
Email: [email protected]
Tel: +44 (0)20 7096 0586

Citigate Dewe Rogerson
Frazer Hall/Mark Swallow
Email: [email protected]
Tel: +44 (0)20 7638 9571

Notes to Editors

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions.

Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for snoring and mild obstructive sleep apnoea, supported by clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnoea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnoea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnoea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

SOURCE Signifier Medical Technologies

Related Links

www.prnewswire.com

Signifier Medical Technologies appoints Philip Hess, former President & CEO of Bose Corporation, as Chief Operating Officer

London, United Kingdom

September 02, 2020

Senior appointment in the US paves the way for the creation of USA operations in preparation for commercialisation of eXciteOSA®, a novel, non-invasive, daytime therapies for sleep-disordered breathing conditions.

Signifier Medical Technologies (“Signifier”), an innovator in the sleep-disordered breathing market, is pleased to announce the appointment of Philip Hess as Chief Operating Officer.

Mr. Hess is the former President & CEO of Bose Corporation, where he worked for 24 years across multiple leadership and operational roles. During his tenure, Mr. Hess was instrumental in Bose’s evolution from a speaker and DVD company to a leader in headsets and wireless products. Most recently, he was leading Bose into connected wearables and health products. He will be located in Boston, MA, where he will have responsibility for growing Signifier’s US infrastructure in preparation for the commercialisation of the company’s products.

Mr. Hess will additionally lead the formation of a new R&D function to identify and leverage innovative science to create new product opportunities for Signifier, aimed at improving the lives of the millions of people with sleep-disordered breathing conditions.

“With Signifier’s clinically-proven technology, we have the opportunity to treat several kinds of sleep disorders in a way never before possible” said Phil Hess. “Sleep is one of the core pillars of health. I’m incredibly excited to be part of a team that will improve the quality of life for millions of people.”

“I am delighted to welcome Phil to the company. He brings a valuable combination of skills and experience that we believe will benefit Signifier not only in the near-term, as we continue the global commercialisation of eXciteOSA®, but also in the future as we seek to build a global innovation-led healthcare company,” added Akhil Tripathi, CEO, and Co-Founder of Signifier Medical Technologies. “Phil is a key partner of this growth strategy. With other recent important appointments in the US and Europe, we are building a highly capable global team to deliver on our ambitions.”

In July, Signifier Medical Technologies announced the appointment of Mr. Matt Sharris as Vice President of Sales for North America. Matt brings strategic and commercial experience in respiratory and medical technologies and this follows the company strategy to drive and maximise the commercial footprint.

For more information, please contact:
Signifier Medical
Email: [email protected]
Tel: +44 (0)20 7096 0586
Citigate Dewe Rogerson

Frazer Hall/Mark Swallow
Email: [email protected]
Tel: +44 (0)20 7638 9571

Notes to Editors

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions.

Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for snoring and mild obstructive sleep apnea, supported by clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

For more information, please visit www.signifiermedical.com.

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

SOURCE Signifier Medical Technologies

Related Links

www.signifiermedical.com
www.prnewswire.com

Signifier® Medical Technologies Appoints New Senior Member to the USA Organization

London, United Kingdom

July 17, 2020

Signifier Medical Technologies, an innovator in the sleep-disordered breathing market, is delighted to appoint Matt Sharris as Vice President of Sales in the North American market. Matt will further enhance and strengthen the organization with his wealth of experience and knowledge in the sleep market space.

This appointment follows the company strategy to drive and maximize commercial footprint later into the year in his geography.

Matt Sharris appointed Vice President of Sales – North America

Mr. Sharris appointed as Vice President of Sales for North America who will bring his strategic and commercial experience in respiratory and medical technologies to help guide Signifier Medical Technologies in the commercialization of its eXciteOSA® device in the region.

This will allow the company to generate interest and education within the health care professional community and managing the KOL platform across North America.

Mr. Sharris was most recently Director of Sales and Vice President of Payor Relations for Regional Home Care, with prior roles within account management and sales for ResMed.

Mr. Sharris is based in Boston.

“Today’s announcement further builds upon the Signifier team globally” said Anshul Sama, CMO and Co Founder of Signifier Medical Technologies. “Each person brings extensive medical technologies backgrounds to the business and will help Signifier strengthen channel partnerships, develop strategic alliances and expand our international sales presence.”

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a demand for new forms of treatment.

About Signifier Medical Technologies

Signifier Medical Technologies, previously known as eXciteOSA®, is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

For more information, please visit www.snoozeal.com

References

1. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
2. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
3. Clinical study of 115 patients with snoring or mild OSA (Apnea-Hypopnea Index (AHI <15)). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period.

For more information, please contact us at:
[email protected]
+44 (0) 207 096 0586